Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2090-4762
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Treatment-naïve idiopathic inflammatory myopathy: disease evaluation by fluorodeoxyglucose versus pyrophosphate ; volume:53 ; number:1 ; day:13 ; month:7 ; year:2022 ; pages:1-11 ; date:12.2022
The Egyptian Journal of Radiology and Nuclear Medicine ; 53, Heft 1 (13.7.2022), 1-11, 12.2022
- Creator
-
Simonsen, Jane A.
Thøgersen, Karin F.
Hvidsten, Svend
Gerke, Oke
Høilund-Carlsen, Poul F.
Diederichsen, Louise P.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s43055-022-00822-z
- URN
-
urn:nbn:de:101:1-2022091521582315663275
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-15T07:20:46+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Simonsen, Jane A.
- Thøgersen, Karin F.
- Hvidsten, Svend
- Gerke, Oke
- Høilund-Carlsen, Poul F.
- Diederichsen, Louise P.
- SpringerLink (Online service)
Other Objects (12)
Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy
Response of treatment-naive brain metastases to stereotactic radiosurgery
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease
Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy
Response of treatment-naive brain metastases to stereotactic radiosurgery
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD
Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease
Quantitative 3D scintigraphy shows increased muscular uptake of pyrophosphate in idiopathic inflammatory myopathy
Response of treatment-naive brain metastases to stereotactic radiosurgery
Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
Cognitive Impairment In Treatment-Naïve Bipolar II and Unipolar Depression
Benefit of [18F]-FDG PET/CT for treatment-naïve nasopharyngeal carcinoma
Naturally occurring mutations to HCV protease inhibitors in treatment-naïve patients
Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naïve glioblastoma
Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia
Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
Choroidal Thickness Changes After Intravitreal Aflibercept Injections in Treatment-Naïve Neovascular AMD